CureVac and Bayer strike deal over Covid-19 vaccine
CureVac, which had said it was looking for a larger partner, started a late-stage clinical trial of its Covid-19 vaccine candidate in December
Berlin — German biotech firm CureVac has agreed an alliance with drugmaker Bayer to help it seek regulatory approval for its experimental Covid-19 vaccine and distribute doses, the two companies said on Thursday.
“Bayer will contribute its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain performance as well as support in selected countries,” they said.
Financial terms were not disclosed.
CureVac, which had said it was looking for a larger partner, started a late-stage clinical trial of its Covid-19 vaccine candidate in December, banking on the same technology that has allowed rivals BioNTech and Moderna to lead the development race.
The collaboration echoes a similar deal by German peer BioNTech, also a research-focused biotech firm, which agreed in 2020 to collaborate with global pharma giant Pfizer on its vaccine, which is now being rolled out globally.
Nasdaq-listed CureVac, which is backed by investors Dietmar Hopp, the Gates Foundation, GlaxoSmithKline and the German government, has said it aims to produce up to 300-million doses of the vaccine in 2021 and up to 600-million in 2022.
In March 2020 , CureVac was at the centre of a row over alleged attempts by US President Donald Trump to gain access to the vaccine, but the company denied at the time having received any US offers for the company or its assets.
Ahead of any regulatory approval, the EU has secured up to 405-million doses of the immunisation, among a slew of supply deals agreed between the bloc and other vaccine developers.
Bayer’s pharma unit, which is trying to build a new cell and gene therapy business, has expertise in cancer, haemophilia, multiple sclerosis, cardiovascular diseases and women’s health, but not in vaccines.
The group’s stock has been battered by billions of euros in writedowns at its agriculture division, litigation woes and a bleaker profit outlook, in large part related to its $63bn takeover of seed maker Monsanto.
Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.